miteman
- MediciNova (NASDAQ:MNOV) shares added ~9% in the premarket on Friday after the biotech announced a patent win related to its long COVID candidate, MN-166 (ibudilast) in the U.S.
- The La Jolla, California-headquartered biopharma said that the U.S. Patent and Trademark Office issued a notice of allowance regarding its pending patent application related to MN-166.
- The Method of Use patent covers the drug’s administration to address several post-COVID conditions. The patent is expected to be valid until at least November 2042.
- A Phase 2/3 trial for ibudilast in long COVID is currently underway as part of a collaboration between MediciNova (MNOV) and the University Health Network, a hospital-based research program in Canada.
- Named Reclaim, the study is expected to support regulatory submissions for the drug with Health Canada.
